AEterna Laboratories, Inc., along with its wholly owned subsidiary, Zentaris GmbH, is a biopharmaceutical company with an extensive product portfolio, including two already-marketed products and 14 others at early- and late-stage development in oncology, endocrinology and infectious diseases. Cetrorelix is sold in the United States and Europe to the in vitro fertilization market, and is in Phase II clinical trials for endometriosis, uterus myoma and enlarged prostate. Miltefosine is sold for black fever and has completed a Phase III trial in parasitic skin disease. Neovastat is in a Phase III trial for non-small cell lung cancer. Perifosine, a novel orally-active AKT inhibitor, is in Phase II trials for multiple cancers. Several other clinical programs are underway. Æterna also owns 62% of Atrium Biotechnologies Inc., which develops and markets ingredients and chemicals in the health and personal care industry for the cosmetics, pharmaceutical, chemical and nutritional sectors.